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Introduction
Fungi can induce a broad spectrum of host responses 
that result in colonization, infection, sepsis, hypersensitivity 
disorders, or toxic reactions. Fungal infections can be classified 
into superficial or deep-seated infections and grouped as 
opportunistic mycoses (such as candidiasis, cryptococcosis, 
and aspergillosis) occurring in immunocompromised hosts or 
as endemic mycoses (such as histoplasmosis, blastomycosis, 
coccidioidomycosis, and penicilliosis) caused by geographically 
restricted fungi infecting otherwise immunocompetent hosts. 
The gamut of immunocompromised host is rapidly expanding 
and also includes debilitated and critically ill medical, surgical 
and intensive care unit (ICU) patients with prolonged hospital 
stays.
As a consequence of the rapidly growing population of 
immunocompromised patients, the spectrum of opportunistic 
invasive fungal infections has increased considerably. Among 
yeasts and molds, Candida and Aspergillus species are the most 
frequent nosocomial fungal pathogens including in the critical 
care setting.1-3 Fungi such as Cryptocococcus, Pneumocystis 
jirovecii, Penicillium marneffei, Zygomycetes, Fusarium, and 
Scedosporium may also cause severe infections in HIV-infected 
patients, onco-hematological and transplants patients, and in 
patients treated with corticosteroids, disease-modifying drugs, 
or monoclonal antibodies directed against immune mediators. 
Given the scope of this special issue of Virulence, this review will 
focus on invasive candidiasis as a cause of sepsis in critically ill 
and ICU patients.
Epidemiology
Approximately 15% of health-care associated infections 
are caused by fungi. Candida accounts for 70–90% of all 
invasive fungal infections and Aspergillus for 10–20%. Recent 
epidemiological studies have shown that invasive mycoses 
increased as a cause of life-threatening infections in critically ill 
and ICU patients. In a one-day, prospective, point prevalence 
study (EPIC II) performed in 2007 which included 7087 infected 
ICU patients from 75 countries, Candida was the third most 
common pathogen with an infection rate of 17%.4 According to 
a survey of the Fungal Infection Network of Switzerland, a third 
of all episodes of Candida bloodstream infections (BSI) occur 
in patients admitted to the ICU.1 The incidence of candidemia 
(ranging between 2 and 6.7 per 1000 admissions) is 5- to 10-fold 
higher in the ICU than in medical or surgical wards. In the 
United States, Candida is at present the third or fourth most 
commonly isolated microorganism in blood cultures accounting 
for 8–10% of BSI. The situation is quite different in Europe since 
Candida is usually between the 6th and 10th positions of blood 
isolates accounting for only 2–3% of BSI.5
Microbiological data collected in recent randomized clinical 
trials of adjunctive therapies for severe sepsis or septic shock 
indicated that fungi are responsible for no more than 5% of 
all cases.6-8 Candida is the most frequent cause of fungal severe 
sepsis or septic shock in ICU patients.9 In a cohort of 386 patients 
with positive blood cultures and septic shock, candidemia 
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invasive fungal infections are an increasingly frequent 
etiology of sepsis in critically ill patients causing substantial 
morbidity and mortality. Candida species are by far the 
predominant agent of fungal sepsis accounting for 10% to 
15% of health-care associated infections, about 5% of all cases 
of severe sepsis and septic shock and are the fourth most 
common bloodstream isolates in the United States. One-third 
of all episodes of candidemia occur in the intensive care setting. 
early diagnosis of invasive candidiasis is critical in order to 
initiate antifungal agents promptly. Delay in the administration 
of appropriate therapy increases mortality. Unfortunately, 
risk factors, clinical and radiological manifestations are quite 
unspecific and conventional culture methods are suboptimal. 
Non-culture based methods (such as mannan, anti-mannan, 
β-d-glucan, and polymerase chain reaction) have emerged 
but remain investigational or require additional testing in 
the iCU setting. Few prophylactic or pre-emptive studies 
have been performed in critically ill patients. They tended 
to be underpowered and their clinical usefulness remains to 
be established under most circumstances. The antifungal 
armamentarium has expanded considerably with the advent 
of lipid formulations of amphotericin B, the newest triazoles 
and the echinocandins. Clinical trials have shown that the 
triazoles and echinocandins are efficacious and well tolerated 
antifungal therapies. Clinical practice guidelines for the 
management of invasive candidiasis have been published by 
the european Society for Clinical Microbiology and infectious 
Diseases and the infectious Diseases Society of North America.
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was documented in 16 patients (4.1%) of whom 10 (2.6%) 
had pure candidemia and 6 (1.5%) mixed candidemia and 
bacteremia.10 Likewise, in the EPISS study, a large prospective 
multicenter study in French ICUs, fungi were identified as 
causative microorganisms in 33 (3.2%) among 1035 patients 
with microbiologically documented infections.11 Conversely, the 
proportion of patients with candidemia who develop severe sepsis 
or septic shock is in the range of 8% to 30% and 23% to 38%, 
respectively.12-14
Invasive Candida infections are associated with high morbidity 
and mortality, especially in the ICU. Overall crude mortality 
among patients with invasive candidiasis or candidemia is in the 
range of 40% to 60%, which reflects in part the contribution 
of the underlying condition.14-16 In the AmarCand study, the 
case fatality ratio was 45.9% and no significant differences 
in mortality were observed between patients with isolated 
candidemia (47.7%) or with invasive candidiasis with (48.7%) or 
without (41.2%) candidemia.15 Of note, in a recent prospective 
study of 271 ICU patients with Candida peritonitis, mortality 
was 38%,17 but death rates in excess of 60% have been reported 
previously.18 The attributable mortality of invasive candidiasis 
was reported to be somewhere between 5% and 71%.16,19,20 This 
wide range probably reflects the inherent difficulty of assessing 
whether these critically ill patients died either with or from fungal 
infections. When complicated by septic shock, candidemia is a 
highly lethal condition with mortality rates beyond 60%.9,10,15,21-24 
Fungal sepsis increased the length of ICUs or hospital stays and 
impacted negatively on treatment costs.25,26
Geography, patient’s age and the use of antifungal agents 
are the main factors impacting on the distribution of Candida 
species. Candida parapsilosis is more frequent in the southern 
hemisphere (Latin America and Australia) or Southern Europe 
than in North America or Northern Europe.27 Candida glabrata 
becomes more frequent with increasing patient’s age. Worldwide, 
Candida albicans was historically the predominant species 
accounting for about two-thirds of Candida infections. However, 
the epidemiology of candidiasis is changing. Over the two last 
decades, species other than C. albicans (primarily C. glabrata, 
C. krusei, C. tropicalis, and C. parapsilosis) have emerged. These 
non-albicans Candida species are now responsible for up to 50% of 
all cases in some centers and are associated with intrinsic resistance 
(C. krusei) or reduced susceptibilities to azoles (C. glabrata) or to 
echinocandins (C. parapsilosis).27 In a prospective, multicenter 
study of 136 patients with candidemia, 42.6% of infections were 
caused by non-albicans Candida. C. glabrata was the second most 
frequent pathogens isolated.15 Susceptibility to fluconazole was 
95.6% for C. albicans strains, but only 68% for non-albicans 
Candida.28 In a retrospective study including 189 patients with 
candidemia in four general ICUs in Greece, Australia, Belgium, 
and Brazil, non-albicans Candida were recovered in 44% of the 
cases.29 Finally, in the prospective AmarCand study, non-albicans 
Candida accounted for 42% of the species. Dose-dependent 
susceptibility or resistance to fluconazole was documented in 
17.1% of Candida isolates.30 Although changes in fungal ecology 
is a complex issue, there is mounting evidence supporting the 
idea that the global shift in the epidemiology of candidemia 
and invasive candidiasis is most likely driven first and foremost 
by a widespread use of antifungal agents, especially azoles. 
These recent trends highlight the importance of and need for 
longitudinal epidemiological studies to monitor changes in the 
distribution of fungal species over time, especially in hospital hot 
spots like the ICU. This information is essential for driving the 
choice of empirical antifungal therapy.
Risk Factors
Candida is part of the normal skin, vaginal, and gastrointestinal 
flora. The vast majority of candidal infections are endogeneous. 
Given its opportunistic nature, Candida will not cause infection 
unless the ecology of the normal flora or the host antifungal 
defense response has been perturbed. Modification of the 
endogenous microbial flora by antibacterial agents is a major 
risk factor allowing for fungal overgrowth on mucosal and skin 
surfaces. Alteration of the physical integrity of the skin and 
mucous membranes barriers by intravascular access devices, 
wounds, surgery, chemotherapy, or of host defenses are other key 
pathogenic elements facilitating dissemination of infection into 
the systemic circulation.
Colonization of mucous membranes and skin is a critical step 
in the pathogenesis of invasive candidiasis. It has been used for 
predicting the development of infections in critically ill patients. 
However, differentiation between colonization and infection is 
not easy. Pioneering work by Pittet et al. in 29 high-risk surgical 
and neonatal ICU patients identified the extent of Candida 
colonization and the severity of illness assessed by APACHE II 
score as independent risk factors for development of infection.31 A 
colonization index of 0.5, defined as the ratio of non-bloodstream 
body site(s) positive for Candida species over the total number 
of body sites tested, successfully identified patients at risk of 
developing invasive infections with a positive predictive value of 
66%. A corrected colonization index (CCI) of 0.4, defined as the 
product of CI times the ratio of the number of heavily colonized 
body sites divided by the total number of body sites colonized, 
had a positive predictive value of 100%. The CCI index was 
validated in an intervention study in ICU patients with historical 
controls confirming the utility of antifungal therapy based on 
colonization.32 In a prospective study involving 92 medical ICU 
patients with prolonged ICU stay, 39.1% of patients with invasive 
Candida infections had a CI of 0.5.33 A CI greater than 0.8 and 
extensive gastro-abdominal surgery was associated with invasive 
Candida in a group of 59 ICU patients.34
Risk factors of the development of invasive fungal infections 
in ICUs patients have been analyzed in numerous retrospective 
studies with a heterogeneous patient population. Various 
conditions including patient’s age, prolonged length of stay, 
administration of broad-spectrum antibiotics, central vascular 
catheters, diabetes mellitus, parenteral nutrition, mechanical 
ventilation, renal insufficiency, hemodialysis, colonization, 
antifungal prophylaxis, surgery, pancreatitis, and treatment 
with corticosteroids and chemotherapy were the most frequently 
identified risk factors. Prior to surgery, Candida colonization, 
acute renal failure, hemofiltration, use of parenteral nutrition, 
www.landesbioscience.com virulence 163
presence of triple lumen catheter, and ICU length of stay were 
factors also identified in prospective studies (Table 1).35-37 Few 
studies have analyzed factors predisposing to the occurrence 
of septic shock.31 In a retrospective cohort of 15 patients, the 
only risk factor was time spent in ICU until the development 
of candidemia.21 APACHE score, delayed administration of 
antifungal therapy, neutropenia, immunosuppression, and 
retention of central venous catheters have been proposed as 
factors of poor prognosis.9,21,22 Studies have yielded conflicting 
results regarding the impact of Candida species isolated from 
blood cultures and patient’s survival.15,38-40 BSI due to C. glabrata, 
C. krusei, and C. tropicalis were reported to be associated with 
the highest mortality in some but not all studies. There was no 
significant relationship between Candida species and death in 
the large AmarCand study.15 The lack of reproducibility of these 
findings is likely to reflect the large heterogeneity of the patient’s 
population and an insufficient power to control for confounding 
factors (i.e., underlying comorbidities, presence of neutropenia or 
the timing to onset of appropriate therapy).
Candida species are commensals of the digestive tract and may 
therefore invade the peritoneal cavity upon perforation of the 
gastrointestinal tract or after surgical section of the intestinal wall. 
Depending upon the underlying condition and circumstances, 
Candida will either be cleared promptly or else cause infection 
which may then disseminate to the bloodstream and other 
organs.41-45 It is not always easy to determine when Candida is 
an “innocent bystander” or when it is playing a pathogenic role. 
In a study of 49 surgery patients with Candida isolated from 
the peritoneal fluid, we reported that recurrent gastrointestinal 
perforation and acute necrotizing pancreatitis were risk factors 
for the development of intra-abdominal candidiasis with a risk of 
systemic dissemination of about 20%.18 Serial semi-quantitative 
cultures indicated that a high initial growth of Candida or an 
increasing amount in follow-up cultures were early indicators of 
infection. Thus, recurrent gastrointestinal leakage with sustained 
seeding of Candida into the peritoneal cavity is a major risk factor 
for infection after surgery.
Predictions Rules and Scoring Systems
Clinical and microbiological prediction rules and scores 
have been developed to identify patients at high risk of fungal 
infections.46-51 Various combinations of clinical, laboratory, and 
management parameters have been utilized to build predictive 
models. Using a stepwise logistic regression model, Michalopoulos 
et al. proposed a model based on four independent risk factors 
(invasive mechanical ventilation ≥10 d, nosocomial bacterial 
infections, cardiopulmonary bypass, and diabetes mellitus) 
that predicted candidemia in cardiothoracic ICU patients.46 
The model was validated in two centers and found to have a 
sensitivity of 57.9%, specificity and positive predictive value 
(PPV) of 100% and a negative predictive value (NPV) of 99.6%. 
In a retrospective study of patients who stayed in a surgical ICU 
for more than 3 d, Phaphitou et al. showed that patients with any 
combination of diabetes mellitus, hemodialysis, total parenteral 
nutrition and broad spectrum antibiotic had an increased rate of 
invasive candidiasis (16.6% vs. 5.1% in patients without these 
characteristics).51 In a follow-up study, Ostrosky-Zeichner et al. 
identified a predictive rule with a negative predictive value of 
97% based on the following parameters: ICU stay of at least 4 d, 
systemic antibiotic therapy, presence of central venous catheter, 
total parenteral nutrition, dialysis, major surgery, pancreatitis, 
use of steroids, or immunosuppressive agents.52 More recently, 
in a very large cohort, Shorr et al. developed a score based on 
age (i.e., less than 65), temperature, altered mental status, 
cachexia, previous hospitalization within 30 d, and mechanical 
ventilation.53 The rates of candidemia increased from 0.4% (when 
no risk factor was present) to 0.8%, 1.6%, 3.2%, 4.2%, 9.6%, 
and 27.3% when the number of risk factors increased from 1 to 
6. Using a retrospective multicenter cohort study of 1699 ICU 
non-neutropenic patients, Leon and colleagues constructed a 
Candida score for patients who stayed in the ICU for at least 7 d.54 
This easy-to-use scoring system relies on four risk factors: total 
parenteral nutrition, surgery, multifocal Candida colonization 
and severe sepsis. A score greater than 2.5 identifed patients at 
risk of developing invasive Candida infections with a sensitivity 
of 81% and a specificity of 74%. The clinical utility of the score 
was then tested in a prospective study that included 1107 ICU 
non-neutropenic patients from Spain, Argentina, and France. 
The incidence rates of invasive candidiasis were 2.3%, 8.5%, 
16.8%, and 23.6% with a Candida score of less than 3, 3, 4, and 
5, respectively. This trend was confirmed in a small prospective 
cohort study in which the rates of invasive candidiasis was 0% in 
patients with a score of 2, 17.6% in patients with a score of 3, and 
50% in patients with a score of 4.55 In the Leon study, a Candida 
score equal to or greater than 3 had a negative predictive value of 
97.7%, a sensitivity of 77.6%, and a specificity of 66.2%.48 These 
data suggest that the main value of the Candida score is to rule 
out invasive candidiasis. The clinical utility of these prediction 
rules and scoring systems on the management of patients should 
be assessed prospectively in larger studies.
Table 1. Risk factors for invasive Candida infections in the critically ill 
patient
Age
Colonization of body sites with Candida
Length of iCU stay
Administration of broad-spectrum antibiotics
intravascular access devices
Diabetes mellitus
Parenteral nutrition
Mechanical ventilation
Renal insufficiency
Hemodialysis, hemofiltration
Antifungal prophylaxis
Surgery
Acute necrotizing pancreatitis
Treatment with corticosteroids
iCU, intensive Care Unit.
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As mentioned above, Candida peritonitis is a difficult 
diagnosis to ascertain. Notwithstanding the issue of infection vs. 
colonization, the presence of Candida in an intraabdominal sample 
should be considered as a marker of disease severity. The isolation of 
yeasts in the peritoneal fluid of patients with community-acquired 
peritonitis was associated with the development of sepsis.56 In a 
retrospective study of 221 ICU patients with peritonitis, Dupont 
et al. developed a score to predict yeast isolation from peritoneal 
samples based on 4 independent risk factors (female gender, a 
proximal gastrointestinal source of peritonitis, intraoperative 
cardiovascular failure, and antimicrobial treatment within 48 h 
of the development of peritonitis).50 When at least 3 risk factors 
were present, the sensitivity and specificity were 84% and 50%, 
respectively.
Clinical Manifestations
The spectrum of Candida infections in critically ill patients 
is rather broad. Clinical manifestations include infections of 
the skin (intertrigo, wound infections), of mucous membranes 
(oropharyngitis, esophagitis, and vulvovaginitis) and of the lower 
urinary tract representing colonization of a urinary catheter 
in most instances. These are usually very mild infections. In 
contrast, infections of deep-seated organs (such as the peritoneum, 
liver, spleen, or the upper urinary tract), of intravascular 
access devices, of the cardiovascular system (i.e., bloodstream 
infections, endocarditis, and septic thrombophlebitis) and 
disseminated infections are normally quite severe and are often 
associated with sepsis, severe sepsis, or septic shock. Occasionally, 
other rare infections like those of the central nervous system 
or mediastinum may be encountered. Candidemia is the most 
common clinical presentation of all forms of invasive candidiasis. 
In a large prospective, multicenter study conducted in 180 ICUs 
in France candidemia was present in more than two-thirds of the 
300 adult patients, of whom 39.5% had primary bloodstream 
infections and 28.4% had invasive candidiasis with secondary 
candidemia. In surgical ICUs, Candida peritonitis is one of the 
most frequent forms of invasive candidiasis.
The clinical presentation of fungal sepsis is not different from 
that of bacterial sepsis. In a prospective, randomized, double-
blind, multiple center study comparing the clinical manifestations 
of septic shock caused by bacteria or Candida spp., higher levels 
of lactate deshydrogenase in patients with bacterial septic shock 
and a higher incidence of renal and hepatic failure in patients 
with candidal septic shock were the only striking differences.10 
Interestingly, the time to onset of sepsis is not a factor that helps 
distinguishing bacterial from fungal etiologies. In a prospective 
study of 136 patients with candidemia, one-third of candidemia 
occurred within the first 5 d of ICU admission.15 The clinical 
manifestations of Candida sepsis are not strain-dependent. In the 
study by Wisplinghoff et al., the inflammatory responses, clinical 
course (development of sepsis, severe sepsis, septic shock) or 
outcome were comparable in patients with bloodstream infections 
caused by C. albicans and non-albicans Candida species.13 Thus, 
with rare exceptions fungal sepsis does not present with specific 
clinical manifestations or laboratory abnormalities and thus 
remains a real challenge for physicians.
Diagnosis
Invasive candidiasis is often fatal unless treated promptly 
with antifungal agents active against the infecting Candida 
species.23,57,58 Hence, the absolute need to initiate prompt 
diagnostic measures. Notwithstanding the problems associated 
with the lack of specificity of risk factors, clinical and radiological 
manifestations, early diagnosis of fungal infection is difficult for 
three main reasons: (1) the yield of blood cultures is typically in 
the range of 50% to 70%,59 (2) identification of the Candida 
species and antifungal susceptibility testing take several days, 
(3) deep tissue sampling is challenging especially in unstable 
patients and may not be possible in thrombocytopenic or 
coagulopathic patients. In patients with hepatic candidiasis, 
biopsy had a sensitivity of 61% in treatment naïve patients which 
dropped to 30% in patients treated with antifungal agents.60 
There is therefore an urgent need to improve our diagnostic 
armamentarium. Non-culture-based diagnostic methods rely 
on the detection of circulating fungal metabolites, antigenic 
components of the fungal cell wall, antibodies, and fungal DNA.
β-d-glucan (BDG)
BDG, a cell wall component of Candida and other fungi 
with the exception of cryptococci and zygomycetes, has been 
proposed as a biomarker of invasive fungal infections. Two 
recent systematic reviews have assessed the performance of 
various commercially available BDG tests for the diagnosis 
of invasive fungal infections.61,62 Most of these studies were 
conducted in hemato-oncological patients with just a few 
focusing on ICU patients. Sensitivities and specificities of BDG 
vary widely, ranging from 57% to 97%, and from 56% to 
93%.62 In patients with proven infections, the pooled sensitivity 
of BDG was 79.1% (95% CI, 68.9–86.7%) and the specificity 
was 87.7% (95% CI, 82.4–91.6%). Based on an analysis of 
11 selected studies, the sensitivity of BDG for the diagnosis of 
probable or proven Candida infections was 75%. A very high 
specificity, positive and negative predictive values were noted 
when two consecutive positive assays were taken into account.61 
Hemodialysis, severe mucositis, systemic bacterial infections, 
antibiotic therapy or human blood products have been linked to 
false positives especially in high-risk patients.63 In a recent study 
in high-risk surgical ICU patients, BDG (Fungitell) was found 
to be superior to colonization indexes and to the Candida score 
for the diagnosis of intra-abdominal candidiasis.64 Sensitivity 
of two consecutive positive tests was 65% and the specificity 
78%. Interestingly, a positive BDG test anticipated the 
diagnosis of intraabdominal candidiasis by a median of 5 d. Of 
note, galactomannan assays are often performed together with 
BDG. A positive BDG and a negative galactomannan suggests 
candidiasis, whereas the reverse suggests of aspergillosis. In 
the recently published Surviving Sepsis Campaign Guidelines, 
BDG was given a 2B grade of recommendation for the diagnosis 
of invasive candidiasis.65
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Mannan and anti-mannan antibodies assays
In a metaanalysis of 14 primarily retrospective studies of 
which seven were conducted in ICU and surgical patients, the 
detection of circulating mannan had a sensitivity of 58% (95% 
CI, 53–62) and a specificity of 93% (95% CI, 91–94) for the 
diagnosis of invasive candidiasis.66 The sensitivity of the anti-
mannan antibody assay was 59% (95% CI, 54–65) and the 
specificity 83% (95% CI, 79–97). Combining the two tests 
increased the sensitivity to 83% (95% CI, 79–87), but it did not 
improve the specificity (86%, 95% CI, 82–90). The sensitivity 
was higher for C. albicans than for C. glabrata or for C. tropicalis. 
In about three quarters of the candidemic patients one of the 
two tests was positive by a mean of 6 to 7 d prior to the results 
of blood cultures. In the Surviving Sepsis Campaign Guidelines, 
mannan and anti-mannan antibody assays were given a 2C grade 
of recommendation for the diagnosis of invasive candidiasis.
Polymerase chain reaction (PCR)
Detection of fungi by PCR is a real challenge. One of main 
reason is that the fungal cell wall interferes with cell lysis and 
the release of DNA resulting in false-negative signals. Fungal 
PCR technology is also prone to false-positive results because of 
exogenous contamination by fungal saprophytes or pathogens. 
It is obviously beyond the scope of this article to discuss the 
difficulties encountered in the development of panfungal 
and species-specific PCR technology and the various steps 
undertaken for improvement.67 Suffice it to say that a great 
diversity of PCR assays (standard, nested, and real-time PCRs) 
and fungal targets (rRNA, cytochrome P450, L1A1, and several 
other genes) have been elaborated and chosen for the detection 
of fungal nucleic acids in the systemic circulation and tissues of 
patients with suspected infections. More than 50 PCR studies 
focusing on the diagnosis of invasive candidiasis were reviewed 
recently.68 PCR turned out to be positive significantly earlier 
than standard culture methods. Overall, the pooled sensitivity 
and specificity for candidemia was 95% and 92%, respectively. 
In 142 surgical patients with bacterial and fungal sepsis, the 
recovery rates of pathogens with the SeptiFast multiplex 
technology were 78.6% for gram-negatives, 50% for fungi, 
and 47.6% for gram-positives. Moreover, detection of pathogen 
by PCR correlated with disease severity even if the blood 
cultures remained negative. Using the same multiplex PCR 
technology for the diagnosis of infection in febrile neutropenic 
cancer patients, Lamoth et al. identified 5 Candida infections 
that were not detected by blood cultures.69 More recently, 
Candida real-time PCR performed in whole blood, plasma or 
serum was compared with the BDG assay in 55 patients with 
invasive candidiasis of whom 17 had candidemia, 33 deep-
seated candidiasis, and 5 a combination of the two.70 Plasma 
or serum PCRs were found to be more sensitive than BDG 
(80% vs 56%; P = 0.03), especially for deep-seated candidiasis 
(88% and 62%), but had similar specificity (70% vs 73%; P 
= NS). The same species of Candida were identified by PCR 
and culture in 82% of the patients. When combining blood 
culture with PCR or BDG the sensitivity reached 98% and 
79%, respectively. In another study, PCR-based pathogen 
detection led to more rapid use of antifungal therapy when 
compared with conventional microbiological methods.25 Most 
recently, the first results of a novel whole blood T2 magnetic 
resonance-based (T2MR) biosensing technology platform were 
published.71 Combining PCR technology and nanoparticle-
based hybridization, the technology allowed a rapid (less than 
3 h), accurate and reproducible detection of 1 CFU per milliliter 
of 5 Candida species. Spiked blood samples analyzed by T2MR 
and conventional blood cultures revealed excellent positive 
(98%) and negative (100%) agreements. Unfortunately, given 
the lack of commercially available tests, fungal PCR assays 
remain at this stage available only in a limited number of skilled 
laboratories and mostly for research purposes only.
Prophylactic, Preemptive,  
and Targeted Antifungal Therapies
Appropriateness and timing of initiation of antifungal therapy 
have a crucial impact on the outcome of invasive candidiasis. 
Several studies have shown that inappropriate empirical 
therapy or delays in the introduction of appropriate antifungals 
are associated with an increased mortality in patients with 
candidemia or septic shock due to Candida.9,57,58,72 Retrospective 
cohort studies demonstrated stepwise increases of mortality as a 
function of the time that elapsed between the first positive blood 
culture and initiation of fluconazole therapy.9,57,58,72 At face value 
these data suggest a role for empirical or preemptive therapy in 
the management of invasive candidiasis. Yet, criteria for initiating 
empirical antifungal therapy in fungal sepsis remain ill defined 
and should be balanced against the potential risks of toxicity, 
selection of resistance, and treatment costs.1,73 In the 2009 clinical 
practice guidelines of the Infectious Diseases Society of America 
(IDSA), it was suggested to consider empirical antifungal therapy 
in critically ill patients with risk factors for invasive candidiasis 
and no other known cause of fever.74 Unfortunately, an early and 
accurate diagnosis of Candida infections is a difficult task and 
the place of Candida scores, colonization indexes, and other non-
conventional diagnostic tools in facilitating the identification of 
patients who may benefit from early interventions remain to be 
established. Antifungal prophylaxis may be reasonable in ICU 
patients with a risk of infection greater than 10%. However, one 
has to acknowledge that this cut-off risk value is quite arbitrary 
and not supported by strong data. Reduction in the rate of 
Candida infections with the use of fluconazole prophylaxis has 
been demonstrated in some clinical trials and metaanalyses.75-79 
However, whether this prophylaxis strategy can provide a survival 
benefit is still controversial.
With the advent of the lipid formulations of amphotericin 
B, the newest triazoles (voriconazole and posaconazole) 
and the echinocandins (caspofungin, anidulafungin, and 
micafungin) the antifungal armamentarium has expanded 
quite substantially. Over the last 2 decades, numerous clinical 
studies have compared the efficacy and safety of the 3 major 
classes of systemic antifungal agents (i.e., polyenes, triazoles, 
and echinocandins) for the management of invasive candidiasis. 
Most of the large phase III clinical trials have enrolled non-
neutropenic patients with candidemia with a limited number 
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of deep-seated Candida infections.39,80-83 These clinical studies 
have shown that triazoles and echinocandins are at least as 
efficacious as and under most instances better tolerated than 
deoxycholate or liposomal amphotericin B with overall response 
rates in the range of 60% to 75%.5 A recent randomized trial 
suggested that anidulafungin might be superior to fluconazole 
as global treatment responses, clinical and microbiological 
successes evaluated at the end of intravenous or of all therapy 
were higher in patients treated with anidulafungin than in 
those treated with fluconazole.84 In the recent review article of 
seven clinical trials by Andes et al., the use of an echinocandin 
therapy also reduced mortality (OR, 0.65; 95% CI 0.45–0.94; 
P = 0.02). Step-down therapy to fluconazole is recommended for 
patients who have improved clinically and who are infected with 
isolates susceptible to fluconazole.81,83,85 Echinocandins should 
also be preferred in case of recent azole exposure or infections 
due to azole-resistant strains (such as C. glabrata). In contrast, 
it might be preferable to use fluconazole for infections due to 
C. parapsilosis because of lower MIC values. However, it remains 
to be demonstrated whether fluconazole therapy translates into 
better clinical and microbiological responses. For non-critically 
ill patients, f luconazole can be used as an empirical therapy for 
suspected invasive Candida infections. Given the increasing 
occurrence of infections by non-albicans Candida species in 
the ICUs, the selection of empirical antifungal therapy should 
always be tailored to local resistance patterns. Finally, until now 
there are no data supporting the superiority of combination 
antifungal therapy over monotherapy.86 A summary of the 
main recommendations of the 2009 guidelines of the Infectious 
Diseases Society of America (IDSA) and of the 2012 guidelines 
of the Fungal Infection Study Group of the European Society 
for Clinical Microbiology and Infectious Diseases (ESCMID) 
for the treatment of candidiasis are shown in Table 2 and in 
Table 3.
Adequate source control improves the outcome of patients 
with severe Candida infections.87 In particular, central venous 
catheter removal has been associated with shorter duration of 
candidemia and reduced mortality.88-90 But this issue remains 
controversial. Indeed, catheter removal was associated with better 
outcome (P = 0.0001) in a study of 1915 patients derived from 
seven recent clinical trials of invasive candidiasis with a patient-
level quantitative assessment.91 In contrast, early (i.e., within 24 
or 48 h after treatment initiation) central venous catheter removal 
did not translate into clinical benefit in a study of 842 patients 
with candidemia who were followed prospectively.92
Conclusions
Fungal infections are associated with high mortality in critically 
ill patients and delayed antifungal treatment contributes to poor 
outcome. As the clinical manifestations of fungal infections are 
non-specific, diagnosis and management of fungal infections 
Table 2. Summary of the iDSA clinical practice guidelines for the management of candidemia in non-neutropenic patients74
Management according to clinical condition 
and microbiological documentation
Recommendations
initial therapy
Fluconazole A-i
echinocandin A-i
Moderately severe to severely ill echinocandin A-iii
Recent azole exposure echinocandin A-iii
Less critically ill and no recent azole exposure Fluconazole A-iii
C. glabrata echinocandin B-iii
C. parapsilosis Fluconazole B-iii
Step-down therapy for clinically stable and 
isolate susceptible to fluconazole
echinocandin to fluconazole A-ii
AmB-d or L-AmB to fluconazole
Duration of therapy
Two weeks after clearance of Candida bloodstream 
infection and resolution of symptoms: A-iii
i.v. catheter removal A-ii
AmB-d, Amphotericin B deoxycholate; L-AmB, Lipid formulation of AmB
Table 3. Summary of the eSCMiD guidelines for initial targeted treatment 
of candidemia and invasive candidiasis93
Antifungal therapy Recommendations
Echinocandins:
Anidulafungin A-i
Caspofungin A-i
Micafungin A-i
Azoles:
Fluconazole C-i
itraconazole D-ii
Posaconazole D-iii
voriconazole B-i
Polyenes:
AmB deoxycholate D-i
AmB colloidal dispersion D-ii
AmB lipid complex C-ii
AmB liposomal B-i
AmB, Amphotericin B.
www.landesbioscience.com virulence 167
remains a challenge. The increase in invasive fungal infections 
and the emergence of other than C. albicans species with reduced 
susceptibilities or intrinsic resistances to azoles highlight the 
absolute need of developing new diagnostic tools that could help 
identify among critically ill patients with invasive candidiasis 
those who may benefit from either prophylactic, preemptive, or 
empirical treatment strategies.
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